Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
bnnbloomberg11h
Merck KGaA Beats Estimates on Boost From Life Science Unit
(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic ...
SDxCentral1d
TileDB Expands Leadership Amid Boost in Pharma Adoption
To support this growth, TileDB opened a new office in New York City, in addition to the company’s current headquarters in Cambridge ... Prior to joining Alexion in 2015, George was employed by Merck & ...
TMCnet2d
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...